{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:31:41Z","timestamp":1749493901073},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00520-024-08498-z","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:02:20Z","timestamp":1713326540000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The emerging emetogenicity of trifluridine\/tipiracil (TAS\u2011102) from patient self-reporting: a multicenter, prospective, observational study"],"prefix":"10.1007","volume":"32","author":[{"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hirate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Matsunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"8498_CR1","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319\u20132326","journal-title":"Oncol Rep"},{"key":"8498_CR2","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto K, Yokogawa T, Ueno H et al (2015) Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA. Int J Oncol 46:2327\u20132334","journal-title":"Int J Oncol"},{"key":"8498_CR3","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F et al (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545\u2013549","journal-title":"Int J Mol Med"},{"key":"8498_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima M, Suzuki N, Emura T et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides. Biochem Pharmacol 59:1227\u20131236","journal-title":"Biochem Pharmacol"},{"key":"8498_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"8498_CR6","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0541","volume":"25","author":"H Fujii","year":"2020","unstructured":"Fujii H, Matsuhashi N, Kitahora M et al (2020) Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist 25:e469\u2013e476","journal-title":"Oncologist"},{"key":"8498_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100093","volume":"6","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Yamazaki K, Oki E et al (2021) Phase II study of trifluridine\/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open 6:100093","journal-title":"ESMO Open"},{"key":"8498_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412\u2013420","journal-title":"Lancet Oncol"},{"key":"8498_CR9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667","journal-title":"N Engl J Med"},{"key":"8498_CR10","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E et al (2017) TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol 18:1172\u20131181","journal-title":"Lancet Oncol"},{"key":"8498_CR11","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"8498_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317","journal-title":"Int J Clin Oncol"},{"key":"8498_CR13","unstructured":"NCCN clinical practice guidelines in oncology: antiemesis, version 1.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 23 Feb 2023"},{"key":"8498_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32:53","journal-title":"Support Care Cancer"},{"key":"8498_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059","journal-title":"JAMA Oncol"},{"key":"8498_CR16","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available online: https:\/\/www.eortc.be\/services\/doc\/ctc\/. Accessed 19 Sep 2022"},{"key":"8498_CR17","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.21873\/anticanres.16400","volume":"43","author":"S Matsuoka","year":"2023","unstructured":"Matsuoka S, Fujii H, Iihara H et al (2023) Emetogenicity and risk factors of nausea and vomiting in patients with metastatic colorectal cancer receiving trifluridine\/tipiracil and bevacizumab chemotherapy. Anticancer Res 43:2351\u20132357","journal-title":"Anticancer Res"},{"key":"8498_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893\u2013899","journal-title":"J Bone Miner Res"},{"key":"8498_CR19","first-page":"70","volume":"4","author":"L Rowbottom","year":"2015","unstructured":"Rowbottom L, Stinson J, McDonald R et al (2015) Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Ann Palliat Med 4:70\u201377","journal-title":"Ann Palliat Med"},{"key":"8498_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663","journal-title":"Support Care Cancer"},{"key":"8498_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23:382\u2013388","journal-title":"Int J Clin Oncol"},{"key":"8498_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u20139","journal-title":"Lancet Oncol"},{"key":"8498_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S et al (2020) Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investig New Drugs 38:507\u2013514","journal-title":"Investig New Drugs"},{"key":"8498_CR24","first-page":"451","volume":"19","author":"A Maleki","year":"2020","unstructured":"Maleki A, Ghadiyani M, Salamzadeh J et al (2020) Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast cancer. Iran J Pharm Res 19:451\u2013464","journal-title":"Iran J Pharm Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08498-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:13:30Z","timestamp":1715591610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8498"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08498-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Fujii has received honoraria for lectures from Ono Pharm, Chugai Pharm, and Taiho Pharm. M Tsuchiya has received honoraria for lectures from Ono Pharm, Chugai Pharm, Taiho Pharm, Sun Pharm and Kyowa Kirin. D Watanabe has received honoraria for lectures from Chugai Pharm. D Hirate has received honoraria for lectures from Taiho Pharm, Daiichi Sankyo, Eli Lilly and Company, Pfizer Eisai, Takeda Pharm, Bristol Myers Squibb, EA Pharma, MSD Japan, Kyowa Kirin, Chugai Pharm, Yakult Honsha, Nippon Kayaku, Eisai, Meiji Seika Pharma, Merck Bio Pharma, AstraZeneca plc and Sun Pharma. Y Ando has received honoraria for lectures from Yakult Honsha, Taiho Pharm, Daiichi Sankyo, Pfizer Eisai. N Matsunami has received honoraria for lectures from Pfizer Eisai, Daiichi Sankyo and Eli Lilly and Company. N Matsuhashi has received both honoraria for lectures and grants made to institution from Taiho Pharm. J Nishimura has received honoraria for lectures from Taiho Pharm. N Inui has received honoraria for lectures from Taiho Pharm, AstraZeneca plc and Chugai Pharm. A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharma, Daiichi Sankyo, Pfizer Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka Pharm, Sandoz, Tsumura, Nipro, Taiho Pharm, Kyowa Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda Pharm, and Nippon Boehringer Ingelheim and grants made to institution from Nippon Kayaku, Asahi Kasei Pharma, Chugai Pharm, Taiho Pharm, Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharm, Sun Pharma and consulting fees from Nippon Kayaku. H Iihara has received honoraria for lectures from Taiho Pharm, Chugai Pharma, Yakult Honsha, Astellas Pharma, Eli Lilly and Company, Daiichi Sankyo, AstraZeneca plc, Nippon Kayaku, Ono Pharm, and Nippon Boehringer Ingelheim; and consulting fees from Pfizer Eisai and Taiho Pharm. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}